Endocrine Abstracts

Despite being the most successful definitive treatment for GD and offering the best response in terms of quality of life, thyroidectomy is rarely performed worldwide. Few studies evaluate its complication rate and potential prognostic factors for complications. We report our last ten years’ experience. Incidence of temporary and permanent hypoparathyroidism, temporary and permanent recurrent laryngeal nerve (RLN) injury and incidental malignancy were recorded, looking for...

Craniopharyngiomas (CPs) are a relatively benign subtype of epithelial tumors that typically originate from the sellar and suprasellar regions of the brain. These endocrine tumors are classified as adamantinomatous (ACP) or papillary (PCP) based on their histological characteristics. Unfortunately, the diagnosis of CPs is frequently made at an advanced stage of tumor development, and therefore relevant associated comorbidities are often present. The first-line treatment is typ...

Pituitary neuroendocrine tumors (PitNETs) constitute approximately 15% of all intracranial tumors and comprise a varied type of neoplasms that, despite being rarely metastatic, can cause severe comorbidities and increased mortality related to the mass effects and hormonal hypersecretion. The high expression levels of somatostatin and dopamine receptors in these tumors has led to the use of somatostatin analogues (SSAs) and dopamine agonists (DAs) as pharmacological treatments....

Background: Pituitary adenomas represent a commonly underestimated pathology in terms of incidence and associated morbimortality. Additionally, some patients poorly respond or develop resistance to current medical treatments [i.e. somatostatin analogues (SSAs) and dopamine agonists]. In this context, it is necessary to develop novel and/or optimize currently available medical therapies. Biguanides (metformin, buformin and phenformin) are antidiabetic drugs that have been descr...

Chimeric somatostatin (SST)/dopamine (DA) compounds, termed dopastatins, such as BIM-23A760, an agonist for SST (sst2 and ss5) and DA (D2) receptors, are emerging as promising new approaches to treat pituitary adenomas. However, their actions and mechanisms on the different types of pituitary tumours are still incompletely understood. Thus, the aim of this study was to analyse a set of key functional parameters (signaling pathways, hormonal expression and secretion, cell viabi...

Pituitary adenomas comprise a heterogeneous group of tumours causing serious comorbidities, which would benefit from identification of novel, common molecular/cellular biomarkers and therapeutic targets. The ghrelin system comprises a complex molecular family with multiple functions, and some of its components have been linked to development of various endocrine-related cancers. In this work we aim at better delineating the patho-physiological significance of the ghrelin regul...

Somatostatin analogs (SSA) are a first-line treatment for pituitary adenomas (PA). Indeed, multi-receptor targeting SSA such as octreotide and pasireotide are being successfully used to control hormone secretion and/or tumor growth. Unfortunately, many PA escape from SSA-therapy, which could be related to somatostatin receptor (sst) presence, abundance, availability and/or signaling. In order to better define the molecular/cellular features associated to octreotide and pasireo...

Craniopharyngiomas are rare benign epithelial tumors derived from remains of Rathke’s pouch. They are more prevalent in childhood, adolescence, and adults <50 years, and, commonly, are usually diagnosed after being associated with serious comorbidities when the development of the tumor is already advanced. To date, first-line therapy is usually surgery, but frequently the resection is not complete, causing high rates of recurrence. Therefore, the identification of ne...

Introduction: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) therapyhas proven effective in type 2 diabetes but there is little data on its effect in patients with psychiatric comorbidity, who usually present worse metabolic and clinical control. The aim of this study was to evaluate if there are differences in the effect of this therapy in relation to the presence of these pathologies.Methods: 225 patients included in a therapy protocol with SGLT2i,...

Pituitary adenomas are heterogeneous, rare tumors, which hinders analysis of large numbers of cases with common approaches. To overcome this, a multicenter, clinical-basic strategy was proposed aimed at enhancing the tools to diagnose and manage pituitary tumors by combining clinical/pathological/molecular information. This initiative was developed by the Sociedad Andaluza de Endocrinología y Nutrición, and further endorsed by the Sociedad Española de Endocrinol...